Last reviewed · How we verify
Acute gonococcal epididymo-orchitis — Treatment Landscape & Competitive Intelligence
2 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Vibramycin | doxycycline | Generic (originally Pfizer) | Tetracycline antibiotic | 72 kDa type IV collagenase, Stromelysin-1, Collagenase 3 | 1967-01-01 | |
| Doxycyclin | Doxycyclin | Bulovka Hospital | 72 kDa type IV collagenase, Stromelysin-1, Collagenase 3 |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- · 1 drug in Acute gonococcal epididymo-orchitis
- Bulovka Hospital · 1 drug in Acute gonococcal epididymo-orchitis
- Generic (originally Pfizer) · 1 drug in Acute gonococcal epididymo-orchitis
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Acute gonococcal epididymo-orchitis:
- Acute gonococcal epididymo-orchitis treatment updates — RSS
- Acute gonococcal epididymo-orchitis treatment updates — Atom
- Acute gonococcal epididymo-orchitis treatment updates — JSON
Cite this brief
Drug Landscape (2026). Acute gonococcal epididymo-orchitis — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/acute-gonococcal-epididymo-orchitis. Accessed 2026-06-10.
Related
- Acute gonococcal epididymo-orchitis full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing